

Table S4: Activity according to biomarker subgroups: Progression free survival (median, IQR, months) in patients with *BRCA1/2* mutations (germline or somatic)

	Confirmed response rate % (95%CI); n/N	N	Median PFS (IQR), months
ATM loss	33.3 (0.8, 90.6); 1/3	3	6.1 (6.1, 8.4)
No ATM loss	22.2 (2.8, 60.0); 2/9	9	7.3 (4.5, 25.4)
Cyclin E1 high	25.0 (0.6, 80.6); 1/4	4	7.3 (4.3, 25.4)
Cyclin E1 low	33.0 (0.8, 90.6); 1/3	3	6.1 (6.1, 8.4)
RAD51 high	16.7 (0.4, 64.1); 1/6	6	8.4 (5.8-25.4)
RAD51 low	20.0 (0.5, 71.6); 1/5	5	6.1 (4.5-undetermined)